NCT02496949View on ClinicalTrials.gov

A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

May 31, 2013

Study Completion Date

August 31, 2013

Conditions
Solid Tumors
Interventions
DRUG

Icaritin

600mg,800mg two doses, Bid, continuous dosing for 56 days, to assess the safety,tolerance,pharmacokinetics and efficacy of icaritin

Trial Locations (1)

100021

Cancer institute & hospital, chinese academy of medical sciences, Beijing

All Listed Sponsors
collaborator

Beijing Shenogen Biomedical Co., Ltd

INDUSTRY

lead

Chinese Academy of Medical Sciences

OTHER

NCT02496949 - A Phase Ib Study to Assess Safety and Efficacy of Oral Icaritin in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter